other material
confidence high
sentiment negative
materiality 0.85
Chemours places CEO and CFO on leave; internal review finds potential material weaknesses; delays 10-K
Chemours Co
- CEO Mark Newman, CFO Jonathan Lock, Controller Camela Wisel placed on administrative leave pending internal review.
- Interim CEO Denise Dignam appointed; Interim CFO Matt Abbott appointed.
- Internal review includes ethics hotline, working capital practices, non-GAAP metrics; evaluating potential material weaknesses in internal control.
- Company delays Q4 2023 earnings release and 10-K filing; will file NT 12b-25.
- Preliminary 2023 net sales ~$6.0B (down 12% YoY); net loss $225-235M vs $578M net income in 2022.